Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Zentalis Pharmaceuticals: Data Due H1 '27 Will Clarify Prospects Of Azenosertib
Zentalis Pharmaceuticals, Inc. earns a cautious Buy rating, driven by azenosertib's potential in Cyclin E1-positive platinum-resistant ovarian cancer (PROC). DENALI and ASPENOVA trials target accelerated and full FDA approval, with pivotal data expected in H1 '27 as a major catalyst. Recent $93m capital raise extends cash runway into 2028, supporting regulatory milestones and mitigating near-term funding risk.
ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?
Zentalis shares climb 28% over the past three months as optimism builds around azenosertib's ovarian cancer program.
Zentalis Pharmaceuticals, Inc. $ZNTL Shares Sold by Almitas Capital LLC
Almitas Capital LLC trimmed its position in Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) by 71.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 457,322 shares of the company's stock after selling 1,141,944 shares during the quarter. Almitas Capital
Zentalis Pharmaceuticals: Late Stage, Lots Of Cash, Crushed By The Market
Zentalis has taken a serious beating in 2025 to date, as the market continues to value their pipeline as a liability rather than an asset. The company is in a bit of a holding pattern for now, but possible approval-worthy data are guided for the end of 2026. The market's disinterest in ZNTL creates a substantial, though risky, potential for upside as data gain more anticipation.
Zentalis Pharmaceuticals, Inc. (ZNTL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 7:00 AM EDT Company Participants Julie Eastland - CEO, President & Director Ingmar Bruns - Chief Medical Officer Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst All right. Good morning, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference.
Zentalis Pharmaceuticals (ZNTL) Loses -46.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Zentalis Pharmaceuticals (ZNTL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zentalis Pharmaceuticals (ZNTL) Upgraded to Strong Buy: What Does It Mean for the Stock?
Zentalis Pharmaceuticals (ZNTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc
FMR LLC (Trades, Portfolio), a prominent investment firm, recently adjusted its holdings in Zentalis Pharmaceuticals Inc (ZNTL, Financial), a clinical-stage biopharmaceutical company. On September 30, 2024, FMR LLC (Trades, Portfolio) reduced its position by 3,600,886 shares, resulting in a new total of 5,075,837 shares.
Zentalis Stock Up as FDA Lifts Partial Hold on Cancer Drug Studies
ZNTL stock gains as the FDA lifts clinical hold on studies of its lead candidate, azenosertib, which is being developed for different cancer indications.
FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers
Monday, the FDA lifted the partial clinical hold on studies of Zentalis Pharmaceuticals, Inc.'s ZNTL azenosertib, the company's novel, selective, and orally bioavailable inhibitor of WEE1.
Zentalis (ZNTL) Plunges More Than 70% in 3 Months: Here's Why
The recent regulatory setbacks related to Zentalis' (ZNTL) lead pipeline candidate, azenosertib, weigh heavily on the stock.
Investors In Zentalis Pharmaceuticals Inc Encouraged To Participate In Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ:ZNTL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
